

NEUROENDOCRINE DISEASE ORIENTED GROUP

CHELSEA HOTEL, TORONTO, ON
ROOM: ROSSETTI

SATURDAY APRIL 29TH, 2023 01:30 PM – 02:30 PM

CO-CHAIRS : DR. SIMRON SIGNH & DR. TIM ASMIS
SENIOR INVESTIGATOR: DR. CHRIS O'CALLAGHAN

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

Learning Objectives:

- To identify and address, through clinical and translational research, the disease burden associated with gastroenteropancreatic neuroendocrine malignancies in Canada.
- To identify clinical trial research opportunities in neuroendocrine malignancies within the Canadian Cancer Trials Group.
- To integrate current knowledge regarding therapeutics and tumour biology of gastroenteropancreatic neuroendocrine malignancies in trial concept development and conduct.
- To interpret and apply new clinical trial methodologies in gastroenteropancreatic neuroendocrine malignancies.
- To provide a learning and mentoring environment supportive to new investigators.

1:30 pm	Welcome	
1:30 pm	NE.1 (NETRETREAT): A Phase II RCT of Lu-177 DOTATATE Retreatment vs. Everolimus in metastatic/unresectable small bowel NET	Dr. S. Singh
1:50 pm	STOPNET (AGITG): – A Randomized Study of Cessation of Somatostatin Analogues after Peptide Receptor Radionuclide Therapy in Mid-Gut Neuroendocrine Tumours	Dr. R. Goodwin Dr. J. Loree
2:10 pm	COMMNETs – Commonwealth Neuroendocrine Tumour Collaboration Update	Dr. T. Asmis
2:20 pm	NCTN NET Taskforce Update	Dr. S. Singh
3:30 pm	Meeting Adjourned	

